Last reviewed · How we verify

Bendrofluazide — Competitive Intelligence Brief

Bendrofluazide (Bendrofluazide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

marketed Calcium-activated potassium channel subunit alpha-1, Carbonic anhydrase 1, Carbonic anhydrase 2 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Bendrofluazide (Bendrofluazide) — Boehringer Ingelheim.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bendrofluazide TARGET Bendrofluazide Boehringer Ingelheim marketed Calcium-activated potassium channel subunit alpha-1, Carbonic anhydrase 1, Carbonic anhydrase 2
Dihydrex BENZTHIAZIDE Ah Robins Inc marketed benzthiazide Calcium-activated potassium channel subunit alpha-1, Carbonic anhydrase 1, Carbonic anhydrase 2 1960-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bendrofluazide — Competitive Intelligence Brief. https://druglandscape.com/ci/bendrofluazide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: